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Abstract 
 
Bone loss and disturbance in the blood cholesterol profiles modulation are two 
effects caused by menopauses syndromes. As the estrogen concentration in the body 
decreased drastically, menopause women need the replacement of estrogen to keep the 
regulation of several physiological functions in the body, such as bone generation and 
cholesterol regulation in a good condition. Phytoestrogen in Carica papaya leaves, such as 
quercetin, could be one of the potential agents for the estrogenic effect. The aim of this 
study is to know the effects of papaya leaf extract (PLE) on the blood cholesterol profiles 
and bone density in ovariectomized rats. Thirty six female Sprague Dawley rats divided into 
six groups.  The groups were sham-treated ovx (S-OVX), ovariectomized rats (OVX), CMC-
Na control (OVX+CMC-Na), positive control (OVX+Estradiol), and the PLE treatment 
groups dose 750 mg/kgBW (OVX+750mg/kgBW) and dose 1000 mg/kgBW (OVX+1000 
mg/kgBW). Administrations of PLE were done in three weeks orally and estradiol 
administrated intraperitonially. In the end of the treatment, the blood sample of tested 
animals was collected for the blood cholesterol determination (LDL, HDL, triglyceride, and 
total cholesterol) and the femur bones were examined for the bone density. Based on the 
results, PLE  dose of 750 mg/kgBW a day in ovariectomized rats showed estrogenic effects in 
modulating blood cholesterol profile by lowering total cholesterol levels. Meanwhile, PLE 
dose of 1000 mg/kgBW significantly increased the bone density (p<0.05). Thus, PLE is 
potential to overcome the negative effects of post-menstrual women especially in the 
cholesterol blood profiles and bone density. 
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INTRODUCTION 
 
Recent studies showed that the 
prevalence of osteoporosis in the world reach 
200 milion cases, and based on The Indonesian 
Department of Health, osteoporosis were 
experienced by around 40 million of population 
in Indonesia (Kosnayani, 2007). Investigation 
of the role of dietary habits on the development 
and prevention of postmenopausal osteoporosis 
has focused primarily on calcium intake and 
vitamin D repletion. These two factors explain 
the development of osteoporosis only in part. 
Based on Prince and Daper (2000), although the 
incidence of osteoporosis in homogeneous 
populations correlates inversely with calcium 
intake, it appears that the incidence of fractures 
is still experienced by the populations with high 
calcium consumption. Since differences in 
nutrition between populations can be striking 
and are not limited to calcium intake, it is 
possible that other macro- and micronutrients 
may contribute to the different incidence of 
fractures between populations. 
Phytoesterogen are a large group of 
heterocyclic phenols with chemical structure 
similar to estradiol. Phytoesterogen are 
abundant in plants and have received increasing 
attention as dietary components that can affect 
several aspects of human health.  
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The notion that phytoesterogen may affect 
osteoporosis favorably has emerged recently 
and is supported by the observations that the 
phytoesterogen are beneficial for manifestations 
of the postmenopausal state such as hyper blood 
cholesterol level and hot flushes. Phytoestrogen 
also plays a role as estrogen agonist which 
benefits in the decrease of bone resorption and 
increase the bone density (Ruggiero and Likis, 
2002).  
Several mechanisms by which 
phytoestrogens reduce blood cholesterol levels 
have been proposed. Similar to that of estradiol, 
first, the cholesterol-lowering effect of 
phytoestrogens is most likely mediated by its 
activation of the LDL receptor. By the 
activation of LDL receptor, the LDL could be 
metabolizedso that LDL level could be 
decreased (Gruber et al., 2002). Second, 
phytoestrogens up-regulate the sterol regulatory 
binding protein 2 (SREBP-2), which in turn 
produces an increase in surface LDL-receptor 
expression (Whitten et al., 2004). Third, 
phytoestrogens decrease blood lipids by their 
action on peroxisome proliferator activated 
receptors (PPARs) (Lunden et al., 2007) 
A recent study showed that bone lost 
induced by ovariectomy prevented by feeding 
rats with diet including phytoesterogen. 
According to Canini et al. (2007), methanolic 
extract of papaya leaves contain quercetin 0.04 
mg/g of 0.25 mg/g of dry leaves. Thus the 
development of papaya leaves as 
phytoestrogens through various studies, in vitro, 
in vivo, and in silico is needed. In this study, in 
vivo experiment was conducted to determine 
the effects of papaya extract on blood 
cholesterol profiles and bone density. 
Hopefully, the results of this study can be used 
as a reference for further research to utilize 
papaya leaves extract (PLE) as an alternative 
source of phytoestrogen. 
 
MATERIALS AND METHODS 
 
Materials 
Papaya leaves were obtained from 
Bantul Yogyakarta, ethanol 70% (E.Merck), 
CMC Na (E. Merck), aquadest, formaldehyde 
(Asia lab), NaCl 0.9 % (PT Otsuka, Jakarta), β-
estradiol(Sigma), corn oil, cholesterol kit 
standard (DSI, Jerman), Plain catgut sutures 
3/0 Meiyi® (Huaian Meiyi Medical Instruments 
Co., Ltd, Jiangsu), antibiotic Enbatic® (PT 
Erela, Semarang). 
 
Papaya Leaves Extract (PLE) 
Papaya leaves were obtained from 
Bantul, Yogyakarta. Determination was 
conducted by Pharmacognosy Laboratory, 
Faculty of Pharmacy, Universitas Gadjah Mada. 
Papaya leaves were dried and powdered before 
the extraction process. The extraction was done 
by ethanol maceration for 5 days. Filtrate 
collected was concentrated by using rotary 
evaporator. 
 
Animals and Treatment 
Thirty six of Female Sprague Dawley 
rats aged 6-7 weeks divided in to 6 groups of 
treatment. The groups are sham-ovariectomized 
(S-OVX), control ovariectomy (OVX), 
ovariectomized+CMC-Na control 
(OVX+CMC-Na), positive control 
(OVX+Estradiol), and the PLE treated groups 
dose 750 mg/kgBW (OVX+750mg/kgBW) and 
dose 1000 mg/kgBW (OVX+1000 mg/kgBW. 
After 3 weeks administrations of PLE, the 
blood was collected from orbital sinus for 
cholesterol profile analysis and animals were 
sacrificed. Ovarium, uterus, mamae, and bone 
density were analyzed. 
 
Analysis of Blood Cholesterol Profiles 
(LDL, HDL, Triglycerides, and Total 
Cholesterol) 
Blood samples taken from the orbital 
sinus were incubated at room temperature 15 
for minutes and centrifuged at 4000 rpm for 20 
min. Serum obtained were used for 
determination of LDL, HDL, triglycerides, and 
total cholesterol by enzymatic-colorimetric 
method. For total cholesterol and triglyceride 
analysis, as many as 10 µL serum were added 1 
ml of serum cholesterol reagent solution (or 
triglyceride reagent solution), and shaken 
gently allowed to stand at room temperature for 
10 minutes and determined for the absorbance 
at λ 546 nm.HDL concentrations were 
determined by the deposition of lipoproteins in 
the exception of LDL, VLDL, and chilomicron 
then continued by enzymatic-colorimetric 
method. Precipitation reagent used was 0.2 ml 
of Mg
2+
 and 0.5 ml of HDL precipitant 
containing MgCl2 (25mmol/L) and 
phosphotungstic acid (0.55 mmol/L). Solution 
mixture were shaken gently and allowed to 
stand at room temperature for 10 minutes and 
then centrifuged at 1200rpm for 2 minutes. The 
precipitate was then separated from the 
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supernatant, HDL concentrations were 
measured with a spectrophotometer containing 
0.1 ml of the supernatant was added 1 ml 
cholesterol reagent then shaken gently and 
allowed to stand at room temperature for 10 
minutes and then determined the absorbance at 
λ 546 nm. For the calculation of the 
concentration of LDL the formula were used: 
The concentration of LDL (mg/dL)=total 
cholesterol concentration–(concentration of 
triglyceride/5+concentration of HDL). ANOVA 
one way (p<0.05) were used to analyze the 
data. 
 
Analysis of Bone Density 
Animal femurs were taken during 
necropsy and were analyzed by X-ray to 
observe the qualitative density profile, whereas 
quantitative analysis is based on the atonation 
linear coefficient and obtained bone density 
values (g/cm
3
). 
 
 
 
RESULTS AND DISCUSSION 
 
Analysis of Blood Cholesterol Profiles 
(LDL, HDL, Triglycerides, and Total 
Cholesterol) 
Ovariectomy was conducted to provide 
estrogen deficiency conditions that represent 
the condition of women in the post-menstrual 
period (menopause). Total cholesterol, LDL, 
HDL, and trigliserida were analyzed by 
enzymatic-colorimetric method to obtain the 
absorbance value of lipid fractions-serum 
reagent complex. The results were shown in 
Fig. 1, OVX experienced a decrease of 
experienced HDLand an increased of LDL, 
triglycerides, and total cholesterol. The control 
estradiol group increased levels of HDL, and 
lower LDL triglycerides, and total cholesterol 
levels. Treatment using PLE gave similar 
results to the control estradiol groups. PLE dose 
of 1000 mg/KgBW decreased total cholesterol 
levels significantly (p<0.05). 
 
Figure 1. Effect of PLEin blood cholesterol profile.Profile of  (A) LDL, (B) HDL, (C) triglycerides, (D) 
total cholesterol.Note (*) indicates a significant effect compared to OVX groups. Analysis 
were done based on one-way ANOVA followed by post-hoc Tuckey HSD (p>0.05). 
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Table I. The value of blood cholesterol profile by enzymatic colorimetric methods 
Groups Total cholesterol 
(mg/dL) 
LDL 
(mg/dL) 
HDL 
(mg/dL) 
Triglyceride 
(mg/dL) 
SOVX 67.3 ± 1.48 31.8 ± 14.2 27.9 ± 4.40 63.1 ± 5.67 
OVX 91.6 ± 10.4 34.6 ± 8.87 22.3 ± 8.30 74.2 ± 31.03 
OVX+CMC Na 67.7 ± 7.67 23.6 ± 0.76 20.0 ± 1.35 85.7 ± 23.28 
OVX+Estradiol 47.8 ± 4.09 16.2 ± 0.95 22.2 ± 3.65 37.1 ± 8.06 
OVX+PLE 750 mg/KgBW 68.1 ± 8.6 23.6 ± 5.25 28.0 ± 2.50 45.5 ± 18.68 
OVX+PLE 1000 mg/KgBW 62 ± 12 21.6 ± 3.48 24.9 ± 4.60 38.3 ± 2.71 
 
Analysis of Bone Density 
The analysis of bone density was 
provided to know the effects of PLE in estrogen 
deficiency condition by ovariectomy. From the 
results using X-rays (Fig.2 and Table II), bone 
density were decreased in ovariectomized 
group, and increased in control estradiol groups 
and also on the treatment of PLE dose 750 and 
1000 mg/kgBW.  
. 
  
 
  
 
 
Figure 2. Effects of PLE on bone density. The results of X-ray bone of (A) Sham-OVX rat group, (B) 
OVX, (C) OVX+CMC-Na, (D) OVX+estradiol, (E) OVX+PLE 750 mg/kg, (F) OVX+PLE 
1000 mg/kg. Red circle sign indicates the condition of the bone density of rat per 
treatment. (G) Average density bone of each group.Note (*) indicates a significant effect 
compared to OVX groups. Analysis were done using on one-way ANOVA followed by post-
hoc Tuckey HSD (p>0.005). 
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Table II. The bone density value 
Groups Density (g/cm3) 
SOVX 0.3497 ± 0.12 
OVX 0.1756 ± 0.02 
OVX+CMC Na 0.2587 ± 0.09 
OVX+Estradiol 0.3137 ± 0.01 
OVX+PLE 750 mg/KgBW 0.4184 ± 0.04 
OVX+PLE 1000 mg/KgBW 0.3769 ± 0.08 
 
It is shown that the bone density profile 
of the ovx-treated groups (OVX) was lower 
than the control sham-ovariectomy (SOVX) 
significantly which related to bone desorption 
in estrogen deficiency condition. Estradiol 
treatment (OVX+estradiol), increased the bone 
density. The treatment of PLE increased the 
bone density, especially at dose 750mg/kgBW. 
These results showed that the treatment of PLE 
improved bone loss in the estrogen deficiency 
condition. The mechanism of how PLE 
increasing bone density is need to be further 
investigated, but it might be the same as the 
mechanism of estrogen in modulating bone 
density. 
In the post-menstrual period, women 
experience estrogen deficiency conditions that 
lead to various changes in the body. The 
menopause women tend to experience the 
abnormalities change in lipid metabolism. 
Disorder of lipid metabolism was characterized 
by increase or decrease in plasma lipid 
fractions. The abnormalities mostly happened 
are the increase in total cholesterol, LDL 
cholesterol, increases in triglyceride levels and 
decrease HDL. 
Estrogen could interact with estrogen 
receptor and influence the formation of HDL 
and LDL receptor so the HDL could be 
increased while LDL is decreased. The 
increased of HDL blood level caused by 
expression of apoA-1 protein which is one of 
the substances important in the formation of 
HDL. Higher expression of apoA-1 increases 
the levels of HDL in the blood (Harnish et al., 
1998). Furthermore, increase levels of HDL in 
the blood will increase the transport of extra 
hepatic LDL to be excreted through the urine. 
Estrogen also play role in LDL level since 
estrogen modulates LDL receptor transcription. 
LDL receptor binds to LDL in the blood 
through the endocytosis mechanism resulting in 
LDL metabolism. Then, LDL is metabolized 
and will be broken down in the liver lysosomes 
(Gent et al., 2004). The metabolism includes 
the role of apolipoprotein and cholesterol ester 
hydrolysis and also cholesterol translocation 
into the cell (Murray et al., 1995). Both of the 
above mechanisms reinforce the reason that 
estrogen can modulate the levels of HDL and 
LDL in the blood. 
In the mechanism of estrogen 
modulating bone density, estrogen affects bone 
remodeling on trabecular and endocortical 
(Prince and Draper, 2000). Estrogen affects the 
activity of osteoblasts and osteoclasts, including 
maintaining the balance of those cells through 
the regulation of the production of paracrine 
factors. Osteoblast cells have estrogen receptors 
ERα and ERβ in the cytosol, thus estrogen 
affects mainly in osteoblast regulation. In the 
differentiation of osteoblast, cellsexpress ERα 
10 times than ERβ (Monroe et al., 2003). Under 
the normal circumstances, circulating estrogen 
in the body will reach osteoblasts, and interacts 
with the estrogen receptors located in the 
cytosol of the cells. Then, this kind of 
mechanism results in the decrease of cytokines 
secretion, such as interleukin-1 (IL-1), 
interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-α), which functions in bone 
resorption. On the other hand, estrogen 
increases the secretion of transforming growth 
factor β (TGF-β), which is the only growth 
factor as the mediator to attract osteoblasts to 
the bone hole caused by osteoclasts activity. 
Thus, osteoblast cells are the primary target 
cells of estrogen to release several growth 
factors and cytokines as described above, and 
indirectly or directly also affect osteoclasts 
(Monroe et al., 2003). 
Conditions of estrogen deficiency lead to 
osteoclastogenesis and bone loss. However, the 
administration of estrogen occurring bone 
remodeling, and decreased production of IL-1, 
IL-6, and TNF-α, as well as the of macrophage-
colony stimulating factor (M-CSF) and RANK-
Ligand (RANK-L). Meanwhile, the estrogen 
also stimulates the expression of 
osteoprotegerin (OPG) and TGF-β 
(Transforming Growth Factor-β) in osteoblasts 
and stromal cells, which would further inhibit 
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bone resorption and increases apoptosis of 
osteoclast cells (Monroe et al., 2003) .The 
results of this study concluded that PLE could 
be a source of phytoestrogens which provide 
estrogenic effects in the cholesterol modulation 
and improved bone density profiles. 
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